TY - JOUR
T1 - Antibody Responses to Fusobacterium nucleatum Proteins in Prediagnostic Blood Samples are not Associated with Risk of Developing Colorectal Cancer
AU - Butt, Julia
AU - Jenab, Mazda
AU - Pawlita, Michael
AU - Overvad, Kim
AU - Tjonneland, Anne
AU - Olsen, Anja
AU - Boutron-Ruault, Marie-Christine
AU - Carbonnel, Franck
AU - Mancini, Francesca Romana
AU - Kaaks, Rudolf
AU - Kühn, Tilman
AU - Boeing, Heiner
AU - Trichopoulou, Antonia
AU - Karakatsani, Anna
AU - Palli, Domenico
AU - Pala, Valeria Maria
AU - Tumino, Rosario
AU - Sacerdote, Carlotta
AU - Panico, Salvatore
AU - Bueno-de-Mesquita, Bas
AU - van Gils, Carla H
AU - Vermeulen, Roel C H
AU - Weiderpass, Elisabete
AU - Quirós, José Ramón
AU - Duell, Eric Jeffrey
AU - Sánchez, Maria-Jose
AU - Dorronsoro, Miren
AU - Huerta, José María
AU - Ardanaz, Eva
AU - Van Guelpen, Bethany
AU - Harlid, Sophia
AU - Perez-Cornago, Aurora
AU - Gunter, Marc J
AU - Murphy, Neil
AU - Freisling, Heinz
AU - Aune, Dagfinn
AU - Waterboer, Tim
AU - Hughes, David J
N1 - ©2019 American Association for Cancer Research.
PY - 2019/9/3
Y1 - 2019/9/3
N2 - BACKGROUND: There is a lack of prospective data on the potential association of Fusobacterium nucleatum (F. nucleatum) and colorectal cancer risk. In this study, we assessed whether antibody responses to F. nucleatum are associated with colorectal cancer risk in prediagnostic serum samples in the European Prospective Investigation into Nutrition and Cancer (EPIC) cohort.METHODS: We applied a multiplex serology assay to simultaneously measure antibody responses to 11 F. nucleatum antigens in prediagnostic serum samples from 485 colorectal cancer cases and 485 matched controls. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CI).RESULTS: We observed neither a statistically significant colorectal cancer risk association for antibodies to individual F. nucleatum proteins nor for combined positivity to any of the 11 proteins (OR, 0.81; 95% CI, 0.62-1.06).CONCLUSIONS: Antibody responses to F. nucleatum proteins in prediagnostic serum samples from a subset of colorectal cancer cases and matched controls within the EPIC study were not associated with colorectal cancer risk.IMPACT: Our findings in prospectively ascertained serum samples contradict the existing literature on the association of F. nucleatum with colorectal cancer risk. Future prospective studies, specifically detecting F. nucleatum in stool or tissue biopsies, are needed to complement our findings.
AB - BACKGROUND: There is a lack of prospective data on the potential association of Fusobacterium nucleatum (F. nucleatum) and colorectal cancer risk. In this study, we assessed whether antibody responses to F. nucleatum are associated with colorectal cancer risk in prediagnostic serum samples in the European Prospective Investigation into Nutrition and Cancer (EPIC) cohort.METHODS: We applied a multiplex serology assay to simultaneously measure antibody responses to 11 F. nucleatum antigens in prediagnostic serum samples from 485 colorectal cancer cases and 485 matched controls. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CI).RESULTS: We observed neither a statistically significant colorectal cancer risk association for antibodies to individual F. nucleatum proteins nor for combined positivity to any of the 11 proteins (OR, 0.81; 95% CI, 0.62-1.06).CONCLUSIONS: Antibody responses to F. nucleatum proteins in prediagnostic serum samples from a subset of colorectal cancer cases and matched controls within the EPIC study were not associated with colorectal cancer risk.IMPACT: Our findings in prospectively ascertained serum samples contradict the existing literature on the association of F. nucleatum with colorectal cancer risk. Future prospective studies, specifically detecting F. nucleatum in stool or tissue biopsies, are needed to complement our findings.
U2 - 10.1158/1055-9965.EPI-19-0313
DO - 10.1158/1055-9965.EPI-19-0313
M3 - Article
C2 - 31481495
SN - 1055-9965
VL - 28
SP - 1552
EP - 1555
JO - Cancer Epidemiology Biomarkers & Prevention
JF - Cancer Epidemiology Biomarkers & Prevention
IS - 9
ER -
